In the context of solid-organ transplantation, minor histocompatibility antigens are derived from polymorphic alleles of genes that differ between the donor and recipient. These minor antigens are presented as peptides on recipient MHC molecules to recipient T cells, which then cause the rejection of the grafted organ. Abstract | Investigations over the past two decades are revealing complexities in the regulation of the innate immune response, and how this response, in turn, controls adaptive immunity. Microbial exposure, infections and tissue damage that accompany solid-organ transplantation result in the release of pathogen-and damage-associated molecular patterns, as well as pathogen-or allograft-derived antigens. Here, we review these triggers of innate and adaptive immunity, and discuss emerging paradigms of the many ways in which infections and tissue damage might directly or indirectly affect alloreactivity and the outcome of transplanted allografts.
Solid-organ transplantation is often the only therapeutic option for end-stage organ failure, but lifelong immuno suppression is necessary to prevent the rejection of allogeneic transplants. High frequencies of alloreactive T cells contribute to the vigour of the allogeneic response that mediates rejection. These alloreactive T cells recognize either allogeneic MHC molecules (a process termed direct allorecognition) or peptides from donor MHC molecules or minor histocompatibility antigens presented on recipient antigen-presenting cells (APCs) (a process termed indirect allorecognition)
. Observations from experimental models indicate that events associated with clinical transplantation, such as ischaemia-reperfusion injury and infections, can enhance alloreactivity and promote rejection episodes through the release of damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs), as well as through alterations in the alloreactive T cell repertoire.
Despite the observed correlation between increased frequencies of infections and acute rejection, especially in the early post-transplant period 1 , definitive clinical proof that infections stimulate alloreactivity is lacking. In a previous review 2 , we discussed the difficulty in making this causal link: immunosuppression used to prevent or treat transplant rejection episodes increases the susceptibility to developing infections but also reduces some of the proinflammatory responses normally elicited by the infections. Furthermore, some infections trigger the release of endogenous corticosteroids that can compromise the proinflammatory response to infection [3] [4] [5] [6] . The prophylactic use of antibiotics, antifungal drugs and antiviral drugs can also reduce the impact of infections on alloreactivity.
Finally, tapering of immunosuppression to treat some types of viral infection 7 may increase the likelihood of rejection, which then makes a definitive demonstration of the direct participation of infections in transplant rejection even more challenging. Nonetheless, paradigms are emerging from experimental models regarding how infections can enhance immune responses in the context of allograft transplantation. We anticipate that these new concepts will lead to renewed investigations in the clinic into whether the timing or type of infection prevents the long-term graft acceptance that is attained by continued pharmacological immunosuppression.
In this Review, we discuss how infections and tissue damage may affect the clinical outcomes of solid-organ transplantation, describe the emerging mechanistic insights based on experimental models, and consider the therapeutic implications arising from these insights.
Timing of infections relative to transplantation
Infections that occur before transplantation include those implicated in the cause of organ failure, such as hepatitis B virus (HBV) or HCV infections in the case of liver damage, and those associated with end-stage disease, such as bacterial and fungal infections in patients with cystic fibrosis and in patients with end-stage renal failure on haemodialysis or peritoneal dialysis 8, 9 . Infections in the post-transplant period are shaped by the type of immunosuppression regimen used, the presence of infections in the donor organ or recipient, and the use of prophylactic antimicrobial agents. These infections are typically divided into those that occur in the first year after transplantation, when the immunosuppression regimen is most intensive, and
Ischaemia-reperfusion injury
Cellular damage caused by the return of blood flow to a tissue after a period of inadequate blood supply. The absence of oxygen and nutrients causes cellular damage and the restoration of blood flow results in inflammation.
those that occur after the first year. Pathogenic bacterial and candidal infections arising from the donor or recipient, as well as from surgical complications, are most prevalent in the first 4 weeks of the post-operative period. Opportunistic infections (such as pneumocystis pneumonia and oral candidiasis) and the activation of latent viral infections (such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), BK polyomavirus, HBV and HCV infections) occur more frequently at 6-12 months post-transplantation. Even when the dose of immunosuppressive therapy is tapered, transplant recipients retain an increased risk of community-acquired respiratory viral infections and urinary tract infections that can lead to secondary bacterial or fungal infections, as well as an increased risk of late viral infections (such as CMV, EBV, HBV, HCV and herpes simplex virus (HSV) infections) (reviewed in REF. 1 ). Both the type and the timing of infection influence its impact on alloreactivity and allograft outcome (FIG. 1) .
Infections before transplantation. An important concept introduced almost 15 years ago is that alloreactive memory T cells are generated not only through sensitization with alloantigens (owing to pregnancies, transfusions or previous transplants), but also through viral infections that promote the induction of memory T cells that cross-react with allogeneic MHC molecules through direct allorecognition 10 (FIG. 2) . This cross-sensitization has been termed heterologous immunity
. The structural basis for heterologous immunity is not completely understood, but experimental evidence supports two main hypotheses. The first hypothesis is molecular mimicry, in which a T cell receptor (TCR) binds directly to allogeneic MHC molecules presenting endogenous (self) peptides in a manner similar to its binding to viral antigens presented by self MHC molecules. The second hypothesis is based on the inherent plasticity of some TCRs, which enables them to mould their ligand-binding loops such that they could use distinct docking modes for the recognition of endogenous peptideallogeneic MHC versus microbial peptide-self MHC complexes (reviewed in REFS 11, 12) . Importantly, the affinity of TCRs for allogeneic MHC molecules can, in some cases, be greater than for self-restricted recognition, further suggesting a functional role for these cross-reactive T cells. For example, the EBV-specific LC13 TCR recognizes syngeneic HLA-B*0801 bound to the EBV epitope FLRGRAYGL with an affinity tenfold lower than that for allogeneic HLA-B*4402 bound to the self peptide EEYLQAFTY (reviewed in REF. 11 ). Similarly, the affinity of the mouse 2C TCR for syngeneic H-2K b presenting the self peptide dEV8 from NADH-ubiquinone oxidoreductase is almost 100-fold lower than its affinity for the allogeneic H-2L d molecule bound with the self peptide p2Ca from α-ketoglutarate dehydrogenase (reviewed in REF. 11 ).
Compared with naive T cells, memory T cells are known to have qualitatively different requirements for activation and to generate immune responses that are faster and more vigorous (reviewed in REF. 13 ). Although T cells with alloreactive specificity exist equally in both the naive and memory T cell compartments 14 , it is likely that memory T cell populations have a more important role in transplant rejection because of their ability to expand more rapidly and express effector molecules such as interferon-γ (IFNγ), granzyme B and perforin, as well as their relative resistance to particular immunosuppressive and tolerance pathways. Indeed, Heeger et al. 15 reported that the pre-transplant frequency of
Box 1 | Basic vocabulary and concepts in transplantation
Autologous, syngeneic and allogeneic grafts Autologous grafts are transplants from one individual to himself or herself; they are usually skin grafts for burns. Syngeneic grafts are transplants between genetically identical individuals, and allogeneic grafts are transplants between genetically distinct individuals of the same species.
Acute and chronic rejection
Acute and chronic rejection are defined by both the timing of rejection (early versus late after transplantation) and the mechanism of rejection. In acute rejection, the mechanism is T cell-or antibody-dependent acute injury, whereas in chronic rejection there is a more progressive loss of function that involves tissue remodelling and both immune-dependent factors (such as T cells and antibodies) and independent factors (for example, drug toxicities).
Direct and indirect allorecognition
Direct allorecognition describes the ability of the recipient's T cells (which are educated in the thymus to be restricted to self MHC molecules) to recognize allogeneic MHC complexes from the donor. This can occur either via molecular mimicry between self MHC-peptide and allogeneic MHC-peptide complexes or via unique T cell receptor (TCR) docking contacts on allogeneic MHC molecules presenting donor peptides. Indirect allorecognition refers to the recognition by recipient T cells of donor peptides that are presented on self MHC molecules of the recipient. Such peptides are processed from allogeneic MHC molecules or from other donor (non-MHC) molecules that have polymorphic differences from host proteins (termed minor histocompatibility antigens).
Heterologous immunity
Heterologous immunity refers to the ability of antigen-experienced T cells of a given specificity to cross-react with a different antigen. In the context of transplantation, this most commonly occurs when memory T cells specific for a microbial antigen cross-react with allogeneic MHC molecules. Because memory T cells are more difficult to suppress than naive T cells, heterologous memory following infections has been hypothesized to be a significant barrier to the induction of transplantation tolerance. donor-specific memory IFNγ-producing lymphocytes in renal transplant patients correlated with the risk of posttransplantation rejection episodes. These observations were confirmed in mice 16 and more recently in nonhuman primates 17 , in which memory T cells were shown to confer resistance to long-term graft acceptance.
The initial experimental demonstration of the importance of heterologous immunity in transplant rejection involved sequential viral infections that generated a population of alloreactive memory CD8 + T cells in mice. These animals then became resistant to the induction of transplant tolerance by co-stimulation blockade and donor-specific transfusion (DST) or by bone marrow chimerism protocols 18 . Data demonstrating the participation of virus-specific T cells in an alloresponse came from studies in which mouse memory CD8 + T cells specific for lymphocytic choriomeningitis virus (LCMV) were generated in vivo through LCMV infection 19 . These LCMV-specific T cells were isolated using LCMV peptide-self MHC tetramers and were shown to be cross-reactive with alloantigens and to induce the acute rejection of skin allografts when transferred into severe combined immunodeficiency mice (SCID mice).
Based on the structural understanding of direct alloreactivity, there is no reason to believe that only viruses can generate heterologous immunity. Indeed, the infection of mice with the parasite Leishmania major was shown to generate memory T cells that are cross-reactive with allogeneic MHC molecules and that prevent the induction of transplant tolerance to subsequent skin grafts 20 . In addition, some bacterial species (such as Staphylococcus and Streptococcus spp.) produce toxins with superantigen properties, which allow them to activate up to 20% of the T cell repertoire in mice, and so these bacteria may also contribute to the generation of alloreactive memory T cells 21 . The ability of infections that occur before transplantation to sensitize alloreactive T cells may be particularly important in light of the potentially rich history of infections in patients waiting for a transplant. Indeed, cross-reactivity between virusspecific T cells and allogeneic HLA molecules has been demonstrated with human T cells 14 , and a remarkable 80% of T cell lines and 45% of T cell clones specific for EBV, CMV, varicella zoster virus or influenza virus cross-react with allogeneic HLA class I or II molecules 22 . Nonetheless, despite widespread acceptance that hetero logous immunity is a demonstrable barrier to successful allograft acceptance in mice, some degree of caution is necessary in extrapolating from studies of T cell cross-reactivity to pathogenicity, and in assuming that hetero logous immunity contributes significantly to the T cell pool that mediates organ allograft rejection in humans. Indeed, it was observed recently that the adoptive transfer of cytotoxic T lymphocytes (CTLs) specific for EBV, CMV and/or adenovirus did not result in greater graft-versus-host disease in human recipients of HLA-mismatched CTLs (with demonstrated broad alloreactivity) than in patients who received HLA-matched CTLs
23
. One possible explanation for this observation is that memory T cells remain dependent on TCR signalling and are therefore susceptible to calci neurin inhibitors, which are essential components of clinical transplantation immunosuppression regimens 24 . Thus, the impact of heterologous immunity and of memory T cells in general may be diminished in clinical transplantation.
In June 2011, belatacept -which is a modified CTLA4 (cytotoxic T lymphocyte antigen 4)-immunoglobulin fusion protein that provides co-stimulatory blockade -was approved as an alternative to calcineurin inhibitors for the prophylactic treatment of rejection in adult kidney transplant recipients 25 . The relative resistance of memory T cells to co-stimulation blockade raises the possibility that belatacept-based regimens may not adequately control memory T cells, and thus the role of these cells in clinical rejection may become more apparent. In patients who have received lung transplants, infections with Chlamydia pneumoniae 26 or Simkania negevensis 27 , and colonization of the allograft by Pseudomonas aeruginosa 28 or Aspergillus spp. 29 , have been associated with the development of acute rejection or bronchiolitis obliterans syndrome. Furthermore, urinary tract infections (especially those occurring late after renal transplantation when prophylactic anti biotics have been discontinued) have been associated with chronic rejection and renal graft loss 30 . When infections occur locally in the 
Graft-versus-host disease
(GVHD). Tissue damage in a recipient of allogeneic tissue resulting from the activity of donor lymphocytes that recognize the tissues of the recipient as foreign. GVHD varies markedly in extent, but it can be life-threatening in severe cases. Damage to the liver, skin and gut mucosa are common clinical manifestations.
Bronchiolitis obliterans syndrome (BOS)
. A fibroproliferative process of the small airways that results in multifocal bronchiolar obliterations and is presumed to reflect chronic Iung allograft rejection. BOS is the major factor that limits the survival of lung transplant recipients.
transplanted organ, graft injury can result from immune responses directed at the pathogen, from the reactivation of alloreactivity and/or from the activation of T cells that recognize cryptic autoantigens exposed following cell damage (FIG. 3) . Despite these reports, unambiguous clinical evidence for a causal relationship between infection and transplant rejection is currently lacking. The question of whether bacterial infections can have direct effects on alloreactivity has been addressed in several experimental settings. We have shown that systemic infections with the intracellular bacter ium Listeria monocytogenes 31 or the extracellular bacterium Staphylococcus aureus 32 induce skin allograft rejection in mice treated with DST and a CD154 (also known as CD40 ligand)-specific antibody to mediate co-stimulation blockade. Interestingly, another common nosocomial infection, P. aeruginosa infection, had no effect on graft acceptance in mice 32 , confirming the clinical observations that only specific bacterial infections are associated with an increased incidence of rejection. These studies suggest that this is due to the different pro-inflammatory cytokines induced by each bacterial strain 32 (see FIG. 2 and below).
Local effects of viral infections are most evident for respiratory viral infections involving influenza virus, parainfluenza virus, rhinovirus, metapneumovirus and respiratory syncytial virus, which can be associated with acute rejection and the development of bronchiolitis obliterans syndrome in patients who have received lung transplants 33 . Although these clinical associations are not definitive and do not demonstrate a causal relationship, they are nonetheless consistent with experimental observations that demonstrate causality [34] [35] [36] [37] [38] [39] . Respiratory infection with Sendai virus at 15-30 days after the orthotopic transplantation of allogeneic tracheas into mice has been shown to enhance the development of chronic rejection 34 . CMV is another frequently occurring infection in the clinic and is associated with increased rates of rejection and graft loss, especially in the absence of prophylactic antiviral drugs 35 . The broad cell tropism of CMV suggests that both local and systemic effects of CMV infection are likely to have an impact on early alloreactivity and long-term graft outcome. Acute infections of mice with mouse CMV (MCMV) in the peri-transplant period across different allogeneic combinations have been shown to prevent Nature Reviews | Immunology graft acceptance 36 , as has the re-activation of latent MCMV infection 37 . Furthermore, the impact of infection on graft survival in mice was greater with some types of viral infection (such as those mediated by LCMV and Pichinde virus) than with other viral infections, and was also increased when infection occurred at or shortly after transplantation 38, 39 . Williams et al. 39 reported that the ability of LCMV infections at the time of transplantation to trigger rejection was not due to the direct participation of LCMV-specific T cells but rather to the stimulation of innate immunity. Specifically, such infections enhanced the maturation of dendritic cells (DCs), leading to the activation of alloreactive T cells in a CD28-and CD40-independent manner (FIG. 2) .
Although clinical data suggest an association between infection and graft outcomes, it is difficult to definitely prove cause and effect. Experimental models have permitted such a demonstration, and the mechanisms by which infections affect graft outcome are just being delineated (see FIG. 2 and below) . Caveats regarding the extrapolation of data derived from mice to the clinic include the differences between experimental and natural routes of infection and the use of immunosuppressants and prophylactic therapies in humans, which may alter the way in which the infections affect alloreactivity. Clinical evidence that Toll-like receptor (TLR) signals promote alloreactivity has been derived from genomic studies of TLR polymorphisms and allograft outcome. In these studies, loss-of-function mutations in the genes encoding TLR2, TLR4, TLR9 and the TLR accessory molecule CD14 were associated with better graft survival but also with an increased incidence of infections [43] [44] [45] [46] . The role of TLRs in promoting allograft rejection has been confirmed experimentally by the delayed rejection kinetics of recipient mice that are deficient in TLR signalling (owing to the deletion of myeloid differentiation primaryresponse gene 88 (Myd88) and/or TIR domain-containing adaptor protein inducing IFNβ (Trif )). In addition, TLR agonists were shown to enhance rejection and prevent graft acceptance [47] [48] [49] [50] [51] . The mechanisms by which TLRs and infections affect alloimmune responses independently of cross-reactivity can be divided into bystander cytokine-mediated effects and cell-intrinsic effects. 
Infections and alloreactivity
Sensing infections. Molecular patterns expressed by microorganisms or released from damaged cells are recognized by various pattern-recognition receptors (PRRs) on or in haematopoietic cells
Toll-like receptors
The cell-surface Toll-like receptors (TLRs) TLR1, TLR2, TLR4, TLR5 and TLR6 recognize components of extracellular bacteria and fungi. In addition, TLR2, TLR4 and TLR13 recognize viral structural proteins. In endosomes, TLR3, TLR7 and TLR8, and TLR9 recognize viral double-stranded RNA, single-stranded RNA and single-stranded DNA, respectively (reviewed in REFS 40, 74) .
C-type lectin receptors
Dectin 1, DC-SIGN (DC-specific ICAM3-grabbing non-integrin), the mannose receptor and MINCLE (macrophageinducible C-type lectin) are transmembrane C-type lectin receptors that recognize classes of carbohydrates expressed on the surface of fungi (reviewed in REFS 40, 74) .
Cytosolic pattern-recognition receptors
Cytosolic pattern-recognition receptors (PRRs) sense cell-intrinsic viral and intracellular bacterial infections and function primarily to trigger the secretion of type I interferons (IFNs) and other factors that recruit and activate dendritic cells (DCs) 74 . These cytosolic PRRs include: retinoic acid-inducible gene I (RIG-I) and melanoma differentiation-associated protein 5 (MDA5), which recognize viral RNA; absent in melanoma 2 (AIM2), DNA-dependent activator of IFN-regulatory factors (DAI; also known as ZBP1) and IFNγ-inducible protein 16 (IFI16), which recognize viral DNA 40 ; and the family of NOD-like receptors (NLRs), which recognize a wide range of pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs), from flagellin and bacterial toxins to particulate antigens, aluminium salts, RNA and low K + concentrations (reviewed in REF. 105 ).
Sensing of live versus dead microorganisms
Live microorganisms have a superior ability to activate innate immune responses compared with attenuated or dead microorganisms. Recently, Sander et al. 106 reported that the mammalian innate immune system directly senses microbial viability through the detection of viability-associated PAMPs (which they termed vita-PAMPs). One such vita-PAMP was identified as prokaryotic mRNA. The prokaryotic mRNA is recognized by cytosolic receptors that activate NLRP3 (NOD-, LRR-and pyrin domain-containing 3) and the TLR adaptor molecule TRIF (TIR domain-containing adaptor protein inducing IFNβ), resulting in the production of active interleukin-1β (IL-1β) and increased levels of interferon-β (IFNβ). Thus, vita-PAMPs provide a mechanism by which the innate immune system modulates its response appropriately to bacterial viability and infectivity.
complemented by studies of patients with genetic defects in cytokine signalling, who have susceptibility to signature infections. For example, genetic deficiencies in the expression of signal transducer and activator of transcription 1 (STAT1), interleukin-12 receptor-β (IL-12Rβ) or IFNγ result in impaired T H 1-type responses and a predisposition to mycobacterial and, to a lesser extent, viral infections 53 . A lack of T H 17 cell differentiation because of loss-of-function mutations in STAT3 or autosomal dominant deficiencies of IL-17RA is associated with susceptibility to candidiasis and S. aureus abscesses 54 . Thus, different classes of host defence response induced by specific infections may result in differentially primed APC populations and cytokine microenvironments that direct specific effector fates of alloreactive T cells (FIG. 2) .
Type I IFNs are produced during viral and intracellular bacterial infections, as well as some extracellular bacterial infections, and their immune-enhancing effects are well documented (reviewed in REF. 55 ). The treatment of recurrent HCV infection in transplant recipients with IFNα is associated with enhanced viral clearance but also with an increased risk of allograft rejection 56 . Experimental studies using a synthetic ligand for TLR3, namely polyinosinic-polycytidylic acid (polyI:C), have confirmed the ability of type I IFNs to prevent skin and islet graft acceptance and to precipitate rejection in mice 57 . IFNβ treatment was shown to prevent the deletion of alloreactive CD8 + T cells, which normally occurs during the induction of tolerance, and to facilitate the priming of these cells in the presence of CD154-specific antibodies 57 . Moreover, we demonstrated that live L. monocytogenes infection prevents the acceptance of skin and heart grafts in mice treated with CD154-specific antibodies and DST 58 . The pro-rejection effects of L. monocytogenes infection were lost in IFNα/β receptor-deficient recipient mice, and IFNβ alone was sufficient to precipitate rejection in recipients treated with CD154-specific antibodies and DST. Thus, systemic infections that promote the early production of type I IFNs can lead to the CD40-independent activation and differentiation of T H 1 cells that mediate allograft rejection.
Systemic infection with S. aureus triggers early IL-6 production that is dependent on the expression of TLR2 and MYD88 by the host 59 . We reported that the pro-rejection effect of S. aureus infection at the time of transplantation in mice was dependent on IL-6 production by cells of the recipient 32 . Furthermore, IL-6 was sufficient to precipitate rejection by enabling naive alloreactive T cells to escape suppression by CD154-specific antibodies and DST and to differentiate into alloreactive T H 1 cells. In a fully mismatched cardiac transplantation model, the administration of CpG oligodeoxynucleotides (ODNs), which are an agonist for TLR9, also triggered IL-6 production and prevented the induction of tolerance by CD154-specific antibodies 60 . This graft rejection was associated with the accumulation of T H 1 and T H 17 cells in cardiac allografts, and was prevented by the simultaneous inhibition of IL-6 and IL-17. Thus, IL-6 production in response to extracellular bacteria or TLR agonists can facilitate the differentiation of bystander alloreactive T cells into T H 1 and T H 17 cells.
How might cytokines produced in response to infections affect immune responses to the allograft through bystander mechanisms? Although cytokines released during APC-T cell interactions have long been thought to signal only locally, observations by Perona-Wright et al. 61 suggest that certain cytokines may be able to diffuse further and modify the majority of lymphocytes in a given lymph node. The authors showed that an inoculation of Heligmosomoides polygyrus or Schistosoma mansoni eggs resulted in permeation of the draining lymph node by IL-4 and the phosphorylation of STAT6 in essentially all CD19 + B cells and most CD4 + and CD8 + T cells within that lymph node. By contrast, infection with Toxoplasma gondii resulted in IFNγ production and STAT1 phosphorylation in the majority of B and T cells in the reactive lymph node 61 . Importantly, IL-4-mediated conditioning of the lymph node prevented subsequent T H 1 cell polarization by Yersinia pestis-pulsed DCs that were injected 7 days later. These effects may be relevant in explaining how infections that trigger strong cytokine production might be able to enhance and skew the effector fates of lymphocytes involved in ongoing alloimmune responses.
Infections in the allograft may also directly lead to enhanced alloreactivity, as suggested by a recent report showing that community-acquired respiratory viral infections in lung transplant recipients are associated with increased levels in the lung of the IFNγ-inducible molecules CXC-chemokine ligand 9 (CXCL9), CXCL10 and CXCL11, which are chemokine ligands for CXCchemokine receptor 3 (CXCR3) 62 . CXCR3 ligands are produced by bronchial epithelial cells and peribronchial mononuclear cells and can recruit activated lymphocytes that are capable of mediating chronic lung allograft rejection 62, 63 . Similarly, the expression of CXCL9 and CXCL10 was markedly elevated in the urine of renal transplant recipients with BK polyomavirus infections compared with the urine of non-infected recipients 64 , and these chemokines are also associated with acute and chronic renal allograft rejection 64, 65 . Thus, cytokines and chemokines produced in response to infection may serve to enhance alloreactivity, either in secondary lymphoid organs or in the allograft itself.
Cell-intrinsic effects on antigen presentation and T cell priming. In addition to bystander cytokine-mediated effects, infections can have direct effects on the uptake and presentation of graft-derived antigens (FIG. 2) . Early studies demonstrated that MYD88-and TRIF-dependent signals in DCs promote the maturation of these cells and their migration to draining lymphoid organs, thereby facilitating the activation of alloreactive T cells 48, 51 . More recently, TLRs have been shown to have additional effects on antigen presentation. Normal tissue homeostasis requires the rapid clearance of dying apoptotic cells in the absence of inflammation, as part of embryonic development and normal tissue turnover 66 . The switch from the homeostatic phagocytosis of apoptotic cells to the induction of host defence immunity has been shown to be regulated by TLRs within the phagosome 67, 68 . The phagocytosis of Escherichia coli-infected apoptotic neutrophils, or of apoptotic B cells carrying lipopoly saccharide (LPS), led to the engagement of TLRs within the phagosome, triggering MYD88-dependent signals that greatly increased the maturation kinetics of the phagosome 67, 69 . This resulted in more efficient delivery of the phagocytic cargo for degradation and increased loading of antigenic peptides onto MHC class II molecules for their presentation to CD4 + T cells. Torchinsky et al. 70 reported that infection-induced TLR engagement in the presence of apoptotic cells also favoured the development of T H 17 cells. Apoptotic signals in the absence of PRR signals triggered the production of anti-inflammatory mediators such as IL-10, transforming growth factor-β (TGFβ) and prostaglandin E2; however, when apoptotic signals were integrated with TLR signals, the secretion of the T H 17-promoting cytokines IL-6, IL-23 and TGFβ was induced 70 . Alloreactive CD4 + IL-17 + cells have been observed in both acute and chronic transplant rejection in humans [71] [72] [73] , but it remains to be elucidated whether these T H 17 cells are generated by cognate mechanisms involving the uptake of apoptotic allogeneic cells that contain microbial PAMPs, as well as through bystander cytokine-mediated effects.
Indirect allorecognition (BOX 1) requires alloantigens to be taken up by recipient APCs and presented on MHC class I or class II molecules to alloreactive T cells. This indirect pathway can have an important role in acute rejection, and it is also considered to be crucial in late rejection, when the donor-derived APCs that are capable of direct presentation to alloreactive T cells have been largely eliminated. Infections within the allograft may result in the simultaneous uptake of alloantigens and PAMPs into the same phagosome, thereby allowing for more effective alloantigen presentation and the promotion of rejection [67] [68] [69] (FIG. 3) . These newly described effects of PRRs on antigen presentation complement the wellestablished enhancement of MHC and co-stimulatory molecule expression on APCs that occurs during infection and results in enhanced T cell priming (reviewed in REF. 74 ). Furthermore, it is possible that antigens shared between the donor and recipient are exposed following infection and cell death. When these antigens are presented in the context of PRR signalling, they could permit the activation of autoreactive T cells that contribute to transplant rejection through direct killing or through the production of pro-inflammatory cytokines (FIG. 3) . This process may explain the detection of autoreactivity -quantified as increased frequencies of T cells or titres of antibodies specific for the self proteins type V collagen, Kα1 tubulin and vimentin 71, 75, 76 -during acute or chronic rejection in lung or kidney transplant recipients.
Effects on established tolerance. A state of transplantation tolerance has not been reliably achieved in human transplantation, although there are promising reports of spontaneous acquisition or deliberate induction of transplantation tolerance in the clinic [77] [78] [79] . Understanding the impact of infections on established tolerance will be necessary for predicting the longevity of the tolerance state but, because of the limited number of patients who exhibit such tolerance, studies addressing this issue have necessarily involved the use of animal models. The in vitro observations by Pasare and Medzhitov 80 introduced the concept that pro-inflammatory cytokines, specifically IL-6, provide an important stimulus that releases effector T cells from the suppression mediated by T Reg cells. These observations raised the possibility that infections, especially those that elicit IL-6, may be able to confer a loss of established tolerance that is maintained by T Reg cells that suppress alloreactive T cells. In an experimental mouse model of heart allograft tolerance, we reported that L. monocytogenes infections occurring 60 days after transplantation can overcome established tolerance and precipitate the acute rejection of established heart allografts 31 . Signalling in recipient mice through the IFNα/β receptor and IL-6 was necessary for the loss of tolerance, and a combination of IFNβ and IL-6 was sufficient to induce rejection. IL-6 induced the proliferation of alloreactive T cells from tolerant mice, whereas IFNβ enhanced IFNγ production by these cells 31 . These data suggest that IL-6 and type I IFNs work synergistically to permit previously suppressed alloreactive T cells to escape regulation, become activated and acquire effector function.
Our and other groups have demonstrated that reversing established tolerance is more difficult than preventing the induction of tolerance. Indeed, LCMV infection during the peri-transplantation period prevented the induction of transplant tolerance in mice, but there was no effect when infection occurred 50 days after transplantation, when tolerance had been established 38 . We reason that acquired mechanisms of donor-specific tolerance are in place in tolerant recipients, and that these mechanisms have to be overcome for alloreactive T cells to become activated. These observations thus bode well for the persistence of tolerance once established, but also underscore the importance of carefully monitoring the state of tolerance, which may be overcome by infections that trigger PRRs and pro-inflammatory cytokine production.
Immunosuppressive effects of infections. Despite the well-characterized pro-inflammatory and pro-rejection effects of infections in experimental models, clinical data suggest that some infections may have systemic immuno suppressive effects. For example, CMV infection is often associated with increased systemic immunosuppression, which predisposes transplant recipients to opportunistic superinfections with fungi, bacteria and other viruses (reviewed in REF. 81 ). Increased rates of coinfections and the reactivation of human herpes virus 6 (HHV6) and HHV7 have been reported, and the course of HCV infection is accelerated in liver transplant recipients who are infected with CMV. In addition, up to a 7-10-fold increase in EBV-associated lymphoproliferative disease has been reported for CMV-infected transplant recipients compared with non-infected recipients (reviewed in REF. 35 ). Finally, although experimental and some clinical studies report an association between CMV infection and acute rejection, other studies do not 82 , in spite of the reduction in immunosuppression that is often instituted to treat CMV infections. These observations collectively raise the possibility that CMV infections may have immunosuppressive effects.
Glucocorticoids
A group of compounds that belong to the corticosteroid family. These compounds can be either naturally produced (hormones) or synthetic. They affect metabolism and have anti-inflammatory and immunosuppressive effects. Many synthetic glucocorticoids (for example, dexamethasone) are used in clinical medicine as anti-inflammatory drugs.
Haptoglobin
A plasma protein that can bind to free haemoglobin in the bloodstream.
The basis for the paradoxical ability of infections to reduce systemic immunity is suggested by experimental studies demonstrating the increase in circulating glucocorticoids during viral infections 3, 5 . Infection with MCMV or respiratory influenza virus was reported to trigger a transient increase in serum levels of glucocorticoids, which blunted pro-inflammatory cytokine production and suppressed systemic immune responses, thereby permitting a more severe secondary bacterial infection 3 . Notably, adrenal corticosterone release is triggered by both viral and bacterial infections 6 . These observations suggest that the release of endogenous glucocorticoids during a wide range of acute infections may transiently induce systemic immunosuppression, resulting in both an increase in the severity of secondary infections and a reduction in alloreactivity.
In summary, experimental data suggest that infections can augment alloreactivity in multiple ways. Infections before transplantation generate heterologous memory T cells that differentiate into potent effector cells to mediate rejection, whereas infections after transplantation can stimulate alloreactivity through PRR engagement and the production of pro-inflammatory cytokines. Infections can also trigger a counter-regulatory immuneadrenal response, resulting in elevated glucocorticoid levels that temper systemic immune responses. Thus, a complex and dynamic relationship can exist between infections and alloreactivity.
Tissue injury and DAMPs
During the transplantation process, tissue damage arises as a result of the brain or cardiac death of the transplant donor, from cold ischaemia (owing to the storage and transport of procured donor organs) followed by reperfusion in the recipient, from warm ischaemia and as a result of the surgical procedure. This tissue damage in the absence of infection, as well as damage as a result of infection, causes the release of DAMPs (FIG. 3) . The number of known DAMPs is increasing, and the list includes extracellular matrix fragments, self nucleic acids, histones and high mobility group protein B1 (HMGB1) (reviewed in REFS 73, 83) . Notwithstanding possible contamination by microbial products, DAMPs can bind to an increasing number of PRRs, including TLR2, TLR3, TLR4, TLR7, TLR9 and receptor for advanced glycation end-products (RAGE; an HMGB1 receptor).
A broad range of PRRs has been implicated in ischaemia-reperfusion injury. In experimental models, ischaemia-reperfusion injury is reduced in hosts deficient in TLR2, TLR4, RAGE or the intracellular PRRs nucleotide-binding oligomerization domain protein 1 (NOD1) and NOD2 . The NLRP3 (NOD-, LRR-and pyrin domain-containing 3) inflammasome is expressed by kidney cells, and its absence also protects from kidney ischaemia-reperfusion injury by reducing cellular necrosis and apoptosis 87 . In a clinical setting, Krüger et al. 88 reported that human kidneys expressing TLR4 mutations that confer a diminished affinity for HMGB1 express lower levels of tumour necrosis factor (TNF) and CC-chemokine ligand 2 (CCL2; also known as MCP1), have higher levels of haem oxygenase 1 and exhibit a higher rate of immediate graft function compared with kidneys expressing wild-type TLR4 alleles.
The better transplantation outcome of poorly matched donor kidney allografts from living donors than well-matched grafts from deceased donors 89 suggests that brain death and cold ischaemia may affect the development of alloreactivity. The ability of DAMPs to enhance alloreactivity has been demonstrated in experimental mouse models using minor histocompatibility antigen-mismatched donor-recipient combinations, which trigger a less robust alloimmune response than MHC-mismatched allografts. These studies showed that DAMPs such as HMGB1, hyaluronan and heparan sulphate, and more recently haptoglobin, enhance alloresponses and graft rejection [90] [91] [92] (reviewed in REF. 93) . Although these data demonstrate that DAMPs can contribute to allograft rejection in situations of limited antigen mismatch, their contribution to alloreactivity and pathogenicity is unclear in situations of MHC mismatch.
DAMPs appear to require different co-receptors and accessory molecules from those used by PAMPs and, as a consequence, DAMPs and PAMPs induce different signalling and pro-inflammatory factors (reviewed in REF. 83 ) and can cooperate to stimulate inflammation and immune responses. For example, HMGB1 synergizes with the TLR4 ligand LPS, the TLR9 ligand CpG ODNs or the TLR1-TLR2 ligand Pam 3 CSK 4 to elicit pro-inflammatory cytokine production 94 . Thus, in transplantation, the crosstalk between DAMPs that arise from tissue damage and PAMPs that arise from post-surgical infections, or possibly from the translocation of bacteria and/or bacterial products from the intestine, may synergistically contribute to the development of alloreactivity and allograft rejection.
Implications for therapy
Can our understanding of how infections alter alloreactivity be translated into improving the outcome of transplantation without decreasing protective immunity to infections? The control of memory alloreactive T cells (whether they have arisen as a result of heterologous immunity or by other means) through the blockade of adhesion molecules has successfully been demonstrated in non-human primate transplantation models. Indeed, antibodies specific for the integrins lymphocyte function-associated antigen 1 (LFA1) and VLA4 (efalizumab and natalizumab, respectively), and an LFA3-immunoglobulin fusion protein (alefacept), effectively prevented the acute rejection of kidney or islet transplants in mice and non-human primates [95] [96] [97] [98] . However, these treatments also diminished protective memory to subsequent infections, which underscores the potential limitation of this approach. Moreover, efalizumab and natalizumab have been associated with an increased risk of progressive multifocal leukoencephalopathy (PML), and efalizumab has been withdrawn from the US market 98 . These concerns prompt the consideration of alternative approaches to minimize the impact of alloreactive memory T cells, for example through the selection of donor-recipient pairs in which the recipient has minimal donor-specific memory T cell reactivity prior to transplantion 17 . Several PRR agonists and antagonists are being developed for the treatment of cancer, autoimmunity and inflammatory diseases and for the prevention of viral and bacterial infections (reviewed in REF. 99 ). In particular, compounds that reduce inflammation or tissue damage may potentially be useful in the setting of transplantation (TABLE 1) . To temper concerns regarding reduced protective immunity to infections, the blocking of PRRs has been explored primarily in experimental models of ischaemia-reperfusion injury, in which the necessity to block TLRs and RAGE [84] [85] [86] is anticipated to be transient. Partial MD2-TLR4 and TLR2 antagonists that are being developed as a treatment for endotoxemia, as well as agents that block HMGB1-RAGE signalling (including soluble RAGE molecules and RAGE-or HMGB1-specific mono clonal antibodies), should attenuate ischaemia-reperfusion injury. In addition, a pharmacological derivative of the TLR5 agonist flagellin that prevents stress-induced apoptosis protected against acute ischaemic renal failure in mice 100 . Nevertheless, even if these strategies are effective at limiting ischaemia-reperfusion injury, it is currently unclear whether they can be safely used in transplant recipients in the immediate posttransplantation period, because this is also the time when infection rates are highest.
Pro-inflammatory cytokines released in response to viral or bacterial infections can enhance alloreactivity and allograft rejection, and the inhibition of type I IFN signalling or of IL-6 has been shown to promote both the induction and maintenance of transplantation tolerance in animal models 31, 32, 58, 60 . The IL-6 receptorspecific monoclonal antibody tocilizumab is already approved for use in patients with rheumatoid arthritis, and a recently completed Phase II clinical trial with the IL-6-specific antibody sirukumab in rheumatoid arthritis also showed promise in terms of efficacy and safety 101 . In a small study of eight patients, tocilizumab was effective in treating corticosteroid-refractory graft-versus-host disease, but infections were the primary adverse events 102 . Indeed, both type I IFNs and IL-6 have pleiotropic effects and play important parts in the control of viral, bacterial and fungal infections, so targeting these cytokines in a safe and efficacious manner in transplant recipients, who are already immunosuppressed, will be challenging.
The ideal therapeutic approach is to block innate immune responses that lead to the stimulation of alloreactivity but not protective immunity to infections. Interestingly, the immunosuppressant rapamycin has been shown to increase the magnitude and quality of effector and memory CD8 + T cell responses to infection but to inhibit alloreactive CD8 + T cell responses 103 . Rapamycin inhibits the maturation of DCs and the secretion of pro-inflammatory and anti-inflammatory cytokines by these cells, enhances DC-mediated antigen presentation by inhibiting autophagy, and inhibits T cell proliferation (reviewed in REF. 104 ). Whether these checkpoints explain the differential effects of rapamycin on alloreactivity and protective immunity is unknown. Nonetheless, these observations provide an important proof-of-concept that graft-specific responses may be selectively attenuated while preserving pathogen-induced responses. 
Conclusions and perspective
The complex effects of infections and tissue damage on the outcome of transplantation are starting to be appreciated. Not only do such events induce the generation of memory alloreactive T and possibly B cells, but they also give rise to PAMPs and DAMPs, which can promote innate immune responses. The tools to analyse the complex feedback circuits between immune responses and
Box 3 | The microbiota and transplantation
Another potential source of pathogen-associated molecular patterns is the commensal microbiota in the host and from donor organs such as the lung, intestine and skin.
Donor microbiota
A putative role for commensal bacterial signals at the time of transplantation in promoting transplant rejection is suggested by the clinical and experimental observations that the lung and intestine, which harbour significant commensal bacterial loads, are more prone to rejection than more sterile organs, such as the heart or kidney (see the US Organ Procurement and Transplantation Network data reports). However, a causal role of local donor commensal microflora in enhancing the immunogenicity of colonized organs remains to be proven.
Recipient microbiota
The bacterial composition of the intestine can shape the repertoire of regulatory T cells, dictate the differentiation of T cells into effector subsets and modulate disease-associated immune responses both locally, for example in inflammatory bowel disease, and distally, for example in autoimmune arthritis (reviewed in REFS 107, 108) . In turn, the immune system can modify the pathogenicity of certain bacteria, as exemplified by the ability of interferon-γ to enhance the virulence of Pseudomonas aeruginosa, transforming it from an indolent colonizer to an invasive pathogen in the intestinal tract 109 . The analysis of the potential role of the recipient microbiota in alloimmune responses is at its infancy, but a recent study 110 analysing the composition of the ileal microbiota following intestinal transplantation indicated that the ratios of phylum Firmicutes to phylum Proteobacteria were markedly decreased in the effluents of patients undergoing acute rejection compared with non-rejecting and pre-rejecting samples. The study did not determine whether the change in the microbiota was a cause or a consequence of the rejection process or whether it could be a useful biomarker to predict patients at risk of rejection. Nonetheless, it underscores the importance of developing further studies to address these questions.
the host microbiota (BOX 3) or infections are just being developed, with some pathways known and some post ulated to have an impact on alloreactivity. It is likely that further study of how these circuits impinge on alloresponses will continue to change our understanding of organ rejection and tolerance, and will provide insights into how the effects of infection on alloreactivity can be controlled without compromising protective immunity.
